Friday, July 12, 2024 3:29:56 PM
How could you know big investors haven't valued the company? IMO, they value a lot. The simple fact is that you can sense it.
Let me ask you a simple question? Do you think Teresa Bitetti, President, Global Oncology Business Unit at Takeda knew about DCVax-L? Of course, she knew. BMS must do some DDs before striking a collaboration trial deal with NWBO which was taken away by Merck later. Is it coincident that Takeda has the aspiration to cure cancer after Teresa Bitetti joined the company? There is no coincidence in biotech.
Now you can take a break.
https://www.takedaoncology.com/about/our-leadership-team/teresa-bitetti/
https://clinicaltrials.gov/study/NCT03014804
https://www.takedaoncology.com/news/our-viewpoints/better-together-our-aspiration-to-cure-cancer/
Let me ask you a simple question? Do you think Teresa Bitetti, President, Global Oncology Business Unit at Takeda knew about DCVax-L? Of course, she knew. BMS must do some DDs before striking a collaboration trial deal with NWBO which was taken away by Merck later. Is it coincident that Takeda has the aspiration to cure cancer after Teresa Bitetti joined the company? There is no coincidence in biotech.
Now you can take a break.
https://www.takedaoncology.com/about/our-leadership-team/teresa-bitetti/
https://clinicaltrials.gov/study/NCT03014804
https://www.takedaoncology.com/news/our-viewpoints/better-together-our-aspiration-to-cure-cancer/
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
